Formulation and pharmacology of long-acting cabotegravir

Current Opinion in HIV and AIDS

Volumn 10, Issue 4, 2015, Pages 239-245

  Trezza, Christine ^a   Ford, Susan L ^a   Spreen, William ^a   Pan, Rennan ^a   Piscitelli, Stephen ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Cabotegravir; Formulation; Long Acting; Nanosuspension; Pharmacokinetics

Indexed keywords

CABOTEGRAVIR; GLUCURONOSYLTRANSFERASE 1A1; LONG ACTING DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PYRIDONE DERIVATIVE;

ANTIVIRAL THERAPY; CLINICAL TRIAL (TOPIC); DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG INTERACTION; DRUG MANUFACTURE; DRUG METABOLISM; ELIMINATION HALF-LIFE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAINTENANCE THERAPY; NANOPHARMACEUTICS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TISSUE DISTRIBUTION; CHEMISTRY; HIV INFECTIONS;

ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; PYRIDONES;

EID: 84943154337     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000168     Document Type: Review

References (22)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services 2014 http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. [Accessed 8 December 2014]
2. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
3. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
4. Margolis DA, Brinson CC, Eron JJ, et al. 744 and rilpivirine as two drug oral maintenance therapy: LAI116482 (LATTE) week 48 results. Proceedings of the 21st Conference on Retroviruses and Opportunistic Infections; 3-6 March 2014; Boston, MA; abstract 91 LB.
5. ClinicalTrials.gov. A phase IIb study to evaluate a long-acting intramuscular regimen for maintenance of virologic suppression (following induction with an oral regimen of GSK1265744 and abacavir/lamivudine) in human immunode ficiency virus type 1 (HIV-1) infected, antiretroviral therapy-naive adult subjects. http://clinicaltrials.gov/ct2/show/NCT02120352?term=gsk1265744&rank=16. [Accessed 8 December 2014].
6. Radzio J, Spreen W, Yueh YL, et al. The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge. Sci Transl Med 2015; 7:270ra5.
7. Andrews CD, Yueh YL, Spreen WR, et al. A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. Sci Transl Med 2015; 7:270ra4.
8. Andrews C, Spreen W, Mohri H, et al. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science 2014; 343:1151-1154.
9. Mundhra D, Pan R. US patent application 20130171214. VIIV Healthcare Company, assignee. Issued 4 July 2013.
10. Bari H. A prolonged release parenteral drug delivery system: an overview. Int J Pharm Sci Rev Res 2010; 3:1-11.
11. Spreen W, Ford SL, Chen S, et al. GSK1265744 pharmacokinetics inplasma and tissue after single-dose long-acting injectable administration in healthy subjects. J Acquir Immune Defic Syndr 2014; 67:481-486.
12. Spreen WR, Margolis DA, Pottage JC Jr. Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS 2013; 8:565-571.
13. Spreen W, Min S, Ford SL, et al. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin Trials 2013; 14:192-203.
14. Zuidema J, Kadir F, Titulaer HAC, Oussoren C. Release and absorption rates of intramuscularly and subcutaneously injected pharmaceuticals (II). Int J Pharm 1994; 105:189-207.
15. Spreen W, Williams P, Margolis D, et al. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults. J Acquir Immune Defic Syndr 2014; 67:487-492.
16. Ford SL, Chiu J, Lovern M, et al. Population PK approach to predict cabotegravir (CAB, GSK1265744) long-acting injectable doses for phase 2b. Proceedings of the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 5-9 September 2014; Washington, DC; abstract H-645.
17. Jackson AG, Else LJ, Mesquita PM, et al. A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for preexposure prophylaxis. Clin Pharmacol Ther 2014; 96:314-323.
18. Spreen W, Rinehart A, Smith K, et al. HIV PrEP dose rationale for cabotegravir (GSK1265744) long-acting injectable nanosuspension. Proceedings of the HIV Research for Prevention; 28-31 October 2014; Cape Town, South Africa; abstract A-671-0009-01071.
19. Culp A, Bowers G, Gould E, et al. Metabolism, excretion, and mass balance of the HIV integrase inhibitor, cabotegravir (GSK1265744) in humans. Proceedings of the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 5-9 September 2014; Washington, DC; abstract H-1010.
20. Reese M, Ford S, Bowers G, et al. In vitro drug interaction profile of the HIV integrase inhibitor, GSK1265744, and demonstrated lack of clinical interaction with midazolam. Proceedings of the 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; 19-21 May 2014; Washington, DC; abstract PP-20. 2014.
21. Ford SL, Gould E, Chen S, et al. Effects of etravirine on the pharmacokinetics of the integrase inhibitor S/GSK1265744. Antimicrob Agents Chemother 2013; 57:277-280.
22. Ford SL, Gould E, Chen S, et al. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744. Antimicrob Agents Chemother 2013; 57:5472-5477.